- Tablets: 16.2 mg phenobarbital, 0.1037 mg hyoscyamine sulfate, 0.0194 mg atropine sulfate, and 0.065 mg scopolamine hydrobromide
- Sustained release tablets: 48.6 mg phenobarbital, 0.311 mg hyoscyamine sulfate, 0.0582 mg atropine sulfate, and 0.0195 mg scopolamine hydrobromide.
- Elixir (per 5ml): 16.2 mg phenobarbital, 0.1037 mg hyoscyamine sulfate, 0.0194 mg atropine sulfate, and 0.0065 mg scopolamine hydrobromide.
DRUG INTERACTIONS: Phenobarbital reduces the blood levels of several drugs by increasing their breakdown in the body. Examples include voriconazole (Vfend), bocepravir (Victrelis), ranolazine (Ranexa), and protease inhibitors (for example, atazanavir [Reyataz], indinavir [Crixivan], saquinavir [Invirase], ritonavir [Norvir]). Belladonna/phenobarbital should not be combined with potassium tablets because belladonna/phenobarbital slows the passage of potassium tablets through the gastrointestinal tract, leading to potassium-induced ulcers and high potassium levels in the blood.
PREGNANCY AND BREASTFEEDING SAFETY: Use during pregnancy has not been adequately evaluated. Pregnant women should use belladonna alkaloid/phenobarbital only when the expected benefit outweighs the potential but unknown risks. Belladonna/phenobarbital are secreted in breast milk and may also reduce milk production.
STORAGE: Belladonna/phenobarbital should be stored at controlled room temperature between 15-30 C (59-86 F)
Quick GuideIBS - Irritable Bowel Syndrome: Symptoms, Diet, Treatment
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.